We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.
- Authors
Hsieh, S.-M.; Chang, S.-V.; Hung, C.-C.; Sheng, W.-H.; Chen, M.-Y.; Chang, S.-C.
- Abstract
Ritonavir-boosted tipranavir (TPV/r) and darunavir (DRV/r) have been approved in patients with virological resistance to multiple protease inhibitors (PIs). Whether the HIV-1 from these patients with virological failure to first-generation PIs remains susceptible to TPV/r or DRV/r is questionable. The susceptibilities of HIV-1 isolates to second-generation PIs in patients who experienced virological failure in three time periods were analysed: 9-2006 to 4-2007 (period 1), 5-2007 to 12-2007 (period 2) and 1-2008 to 8-2008 (period 3). A total of 53 subjects were enrolled, and 51 subject isolates (96.2%) were resistant to ≤1 PIs. The mutation scores for TPV and DRy, and the percentage of isolates with resistance to TPV or DRy, increased significantly from period 1 to period 3. Our data revealed a significant increase in the levels of genotypic resistance to TPV and DRV over the past two years in patients with virological failure to first-generation Pls.
- Subjects
TAIWAN; HIV; MEDICAL virology; PROTEASE inhibitors; TIPRANAVIR (Drug); DARUNAVIR; HIV-positive persons
- Publication
International Journal of STD & AIDS, 2011, Vol 22, Issue 11, p617
- ISSN
0956-4624
- Publication type
Article
- DOI
10.1258/ijsa.2009.009007